Navigation Links
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Date:8/19/2007

-- U.S.-based trial to evaluate four-drug therapy containing highly active

and novel multiple myeloma agents --

CAMBRIDGE, Mass., Aug. 15 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the initiation of a randomized, multi-center, Company-sponsored Phase II trial to evaluate the efficacy of combining VELCADE(R) (bortezomib) for Injection, lenalidomide / dexamethasone and cyclophosphamide in the front-line multiple myeloma (MM) setting. The trial, named EVOLUTION(1), will combine the highly active and noveltherapies of VELCADE and lenalidomide / dexamethasone and also explore the incremental benefit of cyclophosphamide, an alkylating agent, which in previous studies has shown synergistic activity with VELCADE.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The objective of this trial is to evolve the treatment of multiple myeloma by combining these highly active therapies to induce early complete remission and improve long-term survival," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "We are exploring the potential of a new standard of care for patients with newly diagnosed multiple myeloma."

The EVOLUTION trial builds on positive results from previous studies of VELCADE in combination with these agents, showing some of the highest reported complete remission rates. This trial is expected to enroll approximately 100 patients, who will be randomized to either VELCADE, lenalidomide / dexamethasone or VELCADE, lenalidomide / dexamethasone and cyclophosphamide. The primary endpoint of the trial is complete response and very
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
2. Malvern initiates European user group meetings for chemical imaging
3. Genetic Analysis Systems Enter the Clinical Mainstream
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
6. Sygnis Pharma AG announces date for presentation of clinical results
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Trovagene, Inc. (NASDAQ:   TROV), ... results from two clinical studies will be presented at ... urine-based diagnostic test for the detection of high risk ... scheduled to take place in Seattle ... . Additionally, a new U.S. patent was issued earlier ...
(Date:8/20/2014)... Reportlinker.com announces that ... its catalogue: EMR 2014: The Market ... http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html Kalorama has continuously examined ... for nearly a decade, and each year we ... report has become the industry standard, oft-quoted by ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
(Date:8/20/2014)... August 20, 2014 The Workgroup ... nonprofit authority on the use of health IT ... the full agenda for its annual fall conference, ... Efficiency. WEDI-Con 2014 will take place at the ... 2014, attracting a diverse cross-section of payers, providers, ...
(Date:8/20/2014)... Doctors at the University of Hong Kong claim to ... mice by injecting them with a vaccine that changes their ... on its website. Click here to read the full ... Institute of Microbiology created a vaccine using a protein called ... the vaccine is designed to prevent mesothelioma cells from disabling ...
(Date:8/20/2014)... August 20, 2014 Today, Zane Benefits, ... on open enrollment for 2015. , According to Zane ... up in November, employees are encouraged to start thinking ... in 2015, the open enrollment period will run from ... enrollment 2015 individuals can purchase a new individual health ...
(Date:8/20/2014)... The report “Automotive Airbag and ... Global Analysis: by Geography - Trends and Forecasts ... defines automotive airbag and seatbelt market in terms ... growth opportunities in the coming years as well ... restrains, growth indicators, challenges, legislation trends, market dynamics, ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
Breaking Medicine News(10 mins):Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3
... ... Interim Leadership division as senior vice president. A seasoned executive with nearly 20 years of ... , ... 2009 -- B. E. Smith recently hired Deirdre Byrne to lead the firm’s ...
... , MIAMI, Dec. 17 Physicians Healthcare ... today announced that it has issued its financial statements for ... being posted today on the Pink Sheets (www.pinksheets.com). ... , Physicians Healthcare Management Group, Inc. (Phyhealth) is a developer ...
... the employment and sociodemographic characteristics involved in the exposure of ... often work standing up or have to lift heavy objects, ... are frequently exposed to some physical risk in their place ... to exposure to workplace hazards", M Carmen Gonzlez, lead author ...
... PITTSBURGH, Dec. 17 Stem cells that could one day ... easily harvested from the tissue of the umbilical cord, just ... to treat some blood disorders, said University of Pittsburgh School ... the Journal of Biomedicine and Biotechnology . ...
... ... Online , ... Fla. (PRWEB) December 17, 2009 -- Open enrollment has begun for Villanova’s newly online ... schedules can’t accommodate a campus-based program. With the university’s Master of Science in Human ...
... 17 CareFusion Corporation (NYSE: CFN ) announced today ... TRC Capital Corporation (TRC) to purchase up to four million shares ... of common stock outstanding. TRC,s offer price of $23.50 per share ... stock on Dec. 14, 2009, the last full trading day prior ...
Cached Medicine News:Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
... The Shandon Finesse ME+ is designed ... in todays busy laboratories by being one ... microtomes offered today. Excellent for routine wax ... Finesse ME + provides high quality sections ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: